ABVC

ABVC BioPharma (ABVC)

ABVC BioPharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ABVC

1 2 3 4 5 6 7 8 9 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/12/19	22 : 30	GlobeNewswire Inc.	ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21	NASDAQ:ABVC	ABVC BioPharma Inc
2024/12/11	20 : 30	GlobeNewswire Inc.	ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners	NASDAQ:ABVC	ABVC BioPharma Inc
2024/11/16	05 : 31	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/11/16	05 : 30	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/11/16	05 : 28	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/11/16	05 : 26	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/11/15	09 : 33	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/11/14	23 : 25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/11/14	23 : 00	GlobeNewswire Inc.	ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones	NASDAQ:ABVC	ABVC BioPharma Inc
2024/11/14	22 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/11/05	07 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/10/26	01 : 21	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/10/22	21 : 45	GlobeNewswire Inc.	ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners	NASDAQ:ABVC	ABVC BioPharma Inc
2024/10/19	06 : 23	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/09/11	05 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/08/21	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/08/17	05 : 31	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/08/17	05 : 30	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/08/17	05 : 30	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/08/15	20 : 30	GlobeNewswire Inc.	ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements	NASDAQ:ABVC	ABVC BioPharma Inc
2024/08/15	20 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/08/15	04 : 18	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/08/08	06 : 15	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/08/02	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ABVC	ABVC BioPharma Inc
2024/07/27	05 : 30	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:ABVC	ABVC BioPharma Inc
2024/07/24	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/07/13	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/07/13	05 : 00	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/05/24	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/05/24	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc